Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftaroline fosamil - Allergan/Sumitomo Dainippon Pharma/Takeda

Drug Profile

Ceftaroline fosamil - Allergan/Sumitomo Dainippon Pharma/Takeda

Alternative Names: Ceftaroline acetate; CX-0903; DSP-5990; PPI-0903; TAK-599; Teflaro; Zinforo

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Allergan; AstraZeneca; Cerexa; Forest Laboratories; Pfizer; Sumitomo Dainippon Pharma; Wayne State University
  • Class Antibacterials; Azabicyclo compounds; Cephalosporins; Pyridinium compounds; Small molecules; Thiadiazoles
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Registered Bacteraemia
  • Phase II Sepsis
  • No development reported Bacterial infections
  • Discontinued Osteomyelitis

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Bacterial-infections(In adolescents, In children, In infants) in USA (IV, Infusion)
  • 27 Jun 2019 The CHMP of EMA issues a positive opinion recommending modification in existing authorisation for Community-acquired pneumonia and Skin and soft tissue infections to include a wider age group of patients
  • 13 Apr 2019 Adverse events data from a phase II trial in Sepsis presented at 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID -2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top